Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Morgan Stanley Maintains Equal-Weight on Twitter, Raises Price Target to $68

Morgan Stanley analyst Brian Nowak maintains Twitter (NYSE:TWTR) with a Equal-Weight and raises the price target from $62 to $68.

byBenzinga Newsdesk

July 23, 2021

1 minute read

Morgan Stanley analyst Brian Nowak maintains Twitter (NYSE:TWTR) with a Equal-Weight and raises the price target from $62 to $68.

Biolase US Gov’t. Contract Listing On Sam.gov From Dept. Of Veterans Affairs For Co.’s ‘Intent to sole source to Biolase Inc., for their Waterlase Laser Units,’ No Size Disclosed

By Benzinga Newsdesk

Today, 6:50 AM

https://sam.gov/opp/320c6f9003054085882bd4c015161830/view

BIOL

IDEAYA Shares Jump On Positive Interim Data From Eye Cancer Trial

By Vandana Singh

Today, 6:50 AM

The shares of oncology-focused Ideaya Biosciences Inc (NASDAQ: IDYA) are trading higher after interim data from its solid tumor candidate darovasertib with cancer…

IDYA

Wells Fargo Upgrades MaxLinear to Overweight, Announces $66 Price Target

By Benzinga Newsdesk

Today, 6:50 AM

Wells Fargo analyst Gary Mobley upgrades MaxLinear (NASDAQ:MXL) from Equal-Weight to Overweight and announces $66 price target.

MXL

Analyst Ratings

Analyst Ratings for Zions Bancorp

By Benzinga Insights

Today, 6:50 AM

Zions Bancorp (NASDAQ:ZION) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

ZION

Morgan Stanley Maintains Equal-Weight on Twitter, Raises Price Target to $68

Related Posts

Biolase US Gov’t. Contract Listing On Sam.gov From Dept. Of Veterans Affairs For Co.’s ‘Intent to sole source to Biolase Inc., for their Waterlase Laser Units,’ No Size Disclosed

IDEAYA Shares Jump On Positive Interim Data From Eye Cancer Trial

Wells Fargo Upgrades MaxLinear to Overweight, Announces $66 Price Target

Analyst Ratings for Zions Bancorp